About this Medicine article
IMMU-16. Next-generation CAR T-cells targeting IL13RA2 and secreting IL-15 achieve durable tumour clearance in pre-clinical model of diffuse midline glioma by Alastair Hotblack; Patrycja Wawrzyniecka; Gordon Weng-Kit Cheng; Francesco Nannini; Martin Pule; Karin Straathof is a Medicine article available to read on EtoBox.
## Abstract T-cells engineered with a chimeric antigen receptor (CAR) to acquire tumour specificity provide a possible new treatment approach for childhood brain tumours. Durable clinical remissions have been achieved with CD19-directed CAR T-cells in refractory B-cell malignancies including control of leptomeningeal disease and parenchymal deposits. Early clinical data of CAR-T cells in adult glioblastoma and diffuse midline glioma (DMG) further support the rationale for development of CAR-T cell therapy for paediatric high-grade gliomas (pHGG) and other high-risk childhood brain tumours. IL13RA2 provides a suitable CAR target. It is expressed in the majority of pHGG including DMGs while expression is absent on normal (paediatric) brain tissue. Early results with CAR T-cell therapy for adult HGG has shown that IL13RA2 can be safely targeted, and potent anti-tumour activity is possible. However, responses are variable and ultimately transient. This is likely due to the immunosuppressive environment encountered by CAR T-cells at tumour sites which hampers persistent tumour-directed immunity. Here we develop a next generation CAR approach engineering T-cells with both a CAR and a cyt
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Alastair Hotblack; Patrycja Wawrzyniecka; Gordon Weng-Kit Cheng; Francesco Nannini; Martin Pule; Karin Straathof
- Published
- 2022
- Language
- EN
- Field
- Medicine (Health Sciences)